# OnCo record osteosarcoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/osteosarcoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "osteosarcoma" ;
  schema:name "Osteosarcoma"@en ;
  schema:description "Osteosarcoma is the most common bone cancer, mostly in teenagers. Chemotherapy plus surgery cures about two-thirds when it has not spread; because no new drug has beaten that chemotherapy in a large trial in 30 years, the next gains are being sought in cellular therapy against GD2, HER2 and B7-H3."@en ;
  schema:url <https://onco.cc/cancers/osteosarcoma/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Osteosarcoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q549534> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418>, <https://doi.org/10.1016/S1470-2045(16)30214-5>, <https://www.cancer.gov/types/bone/patient/osteosarcoma-treatment-pdq> ;
  onco:tag "gap-fill", "paediatric", "sarcoma", "aya" ;
  onco:related <https://onco.cc/cancers/ewing-sarcoma/>, <https://onco.cc/cancers/chondrosarcoma/>, <https://onco.cc/cancers/chordoma/>, <https://onco.cc/cancers/rhabdomyosarcoma/>, <https://onco.cc/cancers/undifferentiated-pleomorphic-sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/limb-salvage-surgery/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/carbon-ion/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/radioligand-therapy/> ;
  onco:targets <https://onco.cc/targets/gd2/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/b7h3/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/mifamurtide/>, <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/radium-223/> ;
  onco:companies <https://onco.cc/companies/bayer/>, <https://onco.cc/companies/exelixis/>, <https://onco.cc/companies/takeda/>, <https://onco.cc/companies/childrens-oncology-group/> ;
  onco:pathways <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/vegf-angiogenesis/> ;
  onco:terms <https://onco.cc/terms/fnclcc-grade/>, <https://onco.cc/terms/limb-salvage-term/>, <https://onco.cc/terms/histological-response-induction/> ;
  onco:trials <https://onco.cc/trials/euramos-1/>, <https://onco.cc/trials/ccss/>, <https://onco.cc/trials/nct06935409/>, <https://onco.cc/trials/cabone/>, <https://onco.cc/trials/regobone/>, <https://onco.cc/trials/sarc028/> ;
  onco:people <https://onco.cc/people/stefan-bielack/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-marina-lancet-oncol/> ;
  onco:journals <https://onco.cc/journals/journal-of-adolescent-and-young-adult-oncology/> ;
  onco:pipeline <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/drugs/radium-223/>, <https://onco.cc/targets/b7h3/>, <https://onco.cc/drugs/hs-20093/>, <https://onco.cc/drugs/cobolimab/>, <https://onco.cc/drugs/vactosertib/> ;
  onco:standardOfCare <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/mifamurtide/>, <https://onco.cc/technologies/limb-salvage-surgery/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/technologies/carbon-ion/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/drugs/radium-223/> .